Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

In a report released on January 30, Florian Treisch from Kepler Capital maintained a Buy rating on Sage Group plc (SGE – Research Report), ...

Barclays analyst Sven Merkt maintained a Sell rating on Sage Group plc (SGE – Research Report) today and set a price target of £10.80. The ...

AUSTIN, Texas--(BUSINESS WIRE)--Blue Sage Capital, a leading lower-middle market private equity firm, today announced the final close of Blue Sage Capital IV, L.P. (the “Fund”), at $618 ...

Business Insider's personal finance team compared Sage Mortgage to the best mortgage lenders and found it to be a standard lender Sage Mortgage has loan options that should meet most borrowers ...

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

(Reuters) -Britain's Sage Group on Thursday maintained its revenue forecast for fiscal 2025 after the software firm posted 10% growth in first-quarter underlying revenue, driven by higher demand, ...